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Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells and have a tremendous potential to suppress
immune responses. MDSCs accumulate during tumor progression, autoimmunity, chronic infection, transplantation, and other
pathological conditions and can potently suppress T-cell function. Here, we discuss recent ﬁndings that describe the molecular
mechanisms of MDSCs suppressing T-cell immune responses as well as recent observations that MDSCs may have roles in
transplant tolerance.
1.Introduction
Immature myeloid cells (IMCs) are part of the normal pro-
cess of myelopoiesis, which takes place in the bone marrow
and is controlled by a complex network of soluble factors.
Haematopoietic stem cells diﬀerentiate into common myelo-
id progenitor cells and then into IMCs [1]. In normal indivi-
duals, IMCs migrate into diﬀerent peripheral organs, where
they quickly diﬀerentiate into macrophages, dendritic cells,
or granulocytes. However, factors that are produced during
acute or chronic infections, trauma, or sepsis and in the tu-
mor microenvironment promote the accumulation of IMCs
at these sites, prevent their diﬀerentiation, and induce their
activation. These cells exhibit immunosuppressive func-
tionsandarethereforeknownasmyeloid-derivedsuppressor
cells(MDSCs)[2].MDSCsarenotadeﬁnedsubsetofmyelo-
id cells but rather a heterogeneous population of activated
IMCs that have been prevented from fully diﬀerentiating
into mature cells. MDSCs lack the expression of cell-surface
markers that are speciﬁcally expressed by monocytes, macro-
phages, or dendritic cells and comprise a mixture of myeloid
cells that have the morphology of granulocytes or mono-
cytes. Early studies showed that 1–5% of MDSCs can form
myeloidcellcoloniesandthataboutone-thirdofthispopula-
tioncandiﬀerentiateintomaturemacrophagesanddendritic
cells in the presence of the appropriate cytokines in vitro and
in vivo [3].
MDSCs are a heterogeneous population of cells that
consist of myeloid progenitors and immature macrophages,
immature granulocytes, and immature dendritic cells [4].
MDSCs were ﬁrst characterized more than 20 years ago in
tumor-bearing mice and in patients with cancer [5]. There
are many tumor-derived factors that can promote the expan-
sion of MDSCs through the stimulation of myelopoiesis and
inhibit the diﬀerentiation of mature myeloid cells, such as
vascularendothelialgrowthfactor(VEGF),prostaglandinE2
(PGE2), granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF), transforming growth factor-β (TGF-β),
interleukin- (IL-) 1β, IL-10, IL-6, and macrophage colony-
stimulating factor (M-CSF) [6]. Glucocorticoids are also
believed to have inhibitory eﬀects on the maturation of
IMCs. Most tumor-derived factors exert the inhibiting ef-
fects on diﬀerentiation and maturation of myeloid cells
through signal transducer and activator of transcription 3
(STAT3) signaling pathway [7]. In animal tumor models and
cancer patients, MDSCs, induced by tumor-derived factors,
accumulate in large numbers in the blood, bone marrow,
spleen, and tumor masses, mediating the downregulation of
T-cell immunity, thus leading to tumor escape, progression,
and metastasis [8].
Although initial observations and most of the current
information on the role of MDSCs in immune responses
have come from studies in the ﬁeld of cancer research,
accumulating evidence has shown that MDSCs also regulate2 Clinical and Developmental Immunology
Table 1: Summary of phenotype of MDSCs in tumors and transplantation models.
Tumour type Reported phenotype References
Renal cell carcinoma CD11b+/CD14−/CD33+/CD15+
CD66b+/VEGF1+ Rodriguez et al. [16]
Non small cell lung cancer CD11b+/CD14−/CD15+/CD33+ Liu et al. [17]
Colon carcinoma Lin−/HLA-DR−/CD33+/CD11b+ Diaz-Montero et al. [18]
Breast carcinoma Lin−/HLA-DR−/CD33+/CD11b+ Diaz-Montero et al. [18]
Prostate cancer CD14+/HLA-DRlow/neg Vuk-Pavlovi´ ce ta l .[ 19]
Malignant melanoma CD14+/CD11b+/HLA-DRlow/neg Filipazzi et al. [20]
CD80+/CD86+ Poschke et al. [21]
Hepato-cellular carcinoma CD14+/HLA-DRlow/neg H o e c h s te ta l .[ 22, 23]
Hodgkin lymphoma (HL) CD11b+,C D 1 3 +,C D 3 4 +, CD14-, CD45+ Parrinello et al. [24]
Non hodgkin lymphoma CD14+/HLA DRlow/neg/CD120low Lin et al. [25]
Myelodysplastic syndrome (MDS) LIN−/HLA-DR−/CD33+ Wei et al. [26]
Transplantation model Reported phenotype References
Rat kidney allograft CD11b+CD6−CD80/86+NKRP-1+ Dugast et al. [15]
Mouse skin allograft
CD40+/CD80+/F480+/IL-4Rα+ Adeegbe et al. [27]
CD11b+/Gr1+ Zhang et al. [28],
De Wilde et al. [29]
Mouse hepatic islet allograft CD11b+/CD45+ Chou et al. [30]
Mouse cardiac allograft CD11b+/Gr-1int/F4/80+ Turnquist et al. [31]
immune responses during infectious diseases, autoimmune
disorders, and transplantation [9–14]. Evidence for a role of
MDSCs in transplantation is emerging from various animal
models. An expansion of MDSCs was ﬁrst described in a rat
model of kidney allograft tolerance induced by anti-CD28
antibodies [15]. Recently, MDSCs have been considered a
key role in several transplantation models, and study on
the mechanism of MDSC-induced immune suppression may
generate new insights into our understanding of allograft
tolerance and improve therapeutic eﬃciency in transplanta-
tion. In this paper, we discuss the phenotype and subsets, the
mechanisms of suppressive function of MDSCs, and the pos-
sible role of these cells in organ transplantation.
2.PhenotypeandSubsets of MDSCs
MDSCs represent a heterogeneous population of myeloid
cells at diﬀerent stages of diﬀerentiation that comprises mye-
loid progenitor cells and immature myeloid cells (macropha-
ges, granulocytes, and dendritic cells). There is no strict cell-
surface-marker-guided classiﬁcation of MDSC available at
present (Table 1).
In mice, MDSCs are commonly identiﬁed as the cell
membrane that simultaneously expresses two markers: one
is CD11b, an adhesion molecule also known as Mac-1, the
other is Gr1 antigen, a 21–25kDa glycosylphosphatidylino-
sitol- (GPI-) anchored protein. Normal mouse bone marrow
contains 20–30% of cells with this phenotype, but these cells
make up only a small proportion (2–4%) of spleen cells and
areabsentfromthelymphnodes[32].Morerecently,accord-
ing to MDSCs morphological and functional features, as well
as their expression of the two molecules lymphocyte anti-
gen 6 complex, locus C(Ly6C) and lymphocyte antigen 6
complex, locus G(Ly6G), MDSCs were subdivided into
two diﬀerent subsets of granulocytic MDSCs (CD11b+
Ly6G+ Ly6Clow) and monocytic MDSCs (CD11b+ Ly6G−
Ly6Chigh) [33]. In addition to CD11b and Gr1, MDSCs
express additional markers of early myeloid diﬀerentiation,
such as CD31, ER-MP54, and ER-MP58, and low levels of
costimulatorymolecules[34].Someresearchersalsoidentiﬁ-
edamorespeciﬁcpopulationofMDSCsthatexpressGr1and
CD115, which has much stronger suppressive activity com-
pared with the classic Gr1+ CD11b+ MDSCs [35].
In humans, MDSCs are even less well deﬁned owing to
the lack of speciﬁc markers. Human cells do not express a
marker homologous to mouse Gr1. MDSCs are most com-
monly deﬁned as CD14-CD11b+ cells or, more narrowly, as
cells that express the common myeloid marker CD33 but
lack expression of markers of mature myeloid and lympho-
id cells and of the MHC class II molecule HLA-DR [36].
MDSCshavealsobeenidentiﬁedwithinaCD15+population
in human peripheral blood. In healthy individuals, IMCs
constitute ∼0.5% of peripheral blood mononuclear cells.
MDSCs in human were also subdivided into two sub-
sets: granulocytic MDSCs express CD15+ CD33+ CD11b+
with minimal or no HLA-DR expression, while monocytic
MDSCs express CD14 with minimal or no HLA-DR expres-
sion, CD49d (also known as integrin α4) and low levels of
CD15 [37].
The terminally diﬀerentiated granulocytic MDSCs rep-
resent 70–80% of MDSCs. Monocytic MDSCs, accounting
for 20–30% of MDSCs, retain the ability to diﬀerentiate into
mature dendritic cells and macrophages (Table 2). Although
these subsets can have various functions and distributions
depending on their environment, their capacity to induce
T-cell hyporesponsiveness is generally considered equal [38].Clinical and Developmental Immunology 3
Table 2: Phenotype of monocytic and granulocytic MDSCs subsets in murine and human.
Granulocytic MDSCs Monocytic MDSCs
Murine CD11b+ Ly6G+ Ly6C
lowGr-1highCD49d− CD11b+ Ly6G−Ly6C
highGr-1intCD49d+
Human MHC class II
lowCD33+CD11b+ CD14−CD15+ MHC class II
lowCD33+CD11b+ CD14+CD66b+
3. SuppressiveFunction of MDSCs
A growing body of evidence suggests that MDSCs have a
remarkable suppressive eﬀect on T-cell proliferation. Most
studies have shown that the immunosuppressive functions
ofMDSCsrequiredirectcell-cellcontact,whichsuggeststhat
they act either through cell-surface receptors or through the
releaseofshort-livedsolublemediators[4].Here,wewillela-
borate the mechanismsby which MDSCs suppress T-cell res-
ponses and the eﬀects of MDSCs in organ transplantation.
3.1. Arginase-1 (Arg-1) and Inducible Nitric Oxide Synthase
(iNOS). Historically, the suppressive activity of MDSCs has
been associated with the metabolism of L-arginine. L-argini-
ne serves as a substrate for two enzymes, iNOS (which gene-
rates NO) and Arg-1 (which converts L-arginine to urea and
L-ornithine). MDSCs express high levels of both Arg-1 and
iNOS, and a direct role for both of these enzymes in the inhi-
bition of T-cell function is well established [39].
Although the ﬁrst experiments underlying the impor-
tance of L-arginine metabolism in cancer were performed
more than 50 years ago, only recently has the role of Arg-1
in tumor growth and escape from the immune surveillance
been clariﬁed [40]. Arg-1 can be released or expressed by
either cancer cells or tumor-associated myeloid cells, includ-
ing putative MDSCs. Recent data suggest that there is a
close correlation between the availability of L-arginine and
the regulation of T-cell proliferation. The increased activity
of Arg-1 in MDSCs leads to enhanced L-arginine cataboli-
sm, which depletes this nonessential amino acid from the
microenvironment. The shortage of L-arginine inhibits T-
cell proliferation through several diﬀerent mechanisms, in-
cluding decreasing their expression of CD3 ζ-chain and pre-
venting their upregulation of the expression of the cell cycle
regulators cyclin D3 and cyclin-dependent kinase 4 [41]. An
expansion of MDSCs was detected in immunoglobulin-like
transcript 2 (ILT2) transgenic mice [28]. In this model, ado-
ptivetransferofMDSCsfromILT2micesigniﬁcantlydelayed
the rejection of major MHC-II-mismatched skin allografts.
This eﬀect was associated with a unique MDSCs transcrip-
tional proﬁle including upregulation of Arg-1, but not iNOS.
Highﬁll et al. [42] found that exogenous IL-13 produced
an MDSCs subset that was more potently suppressive and
resulted in Arg-1 upregulation. These MDSCs were more ef-
fective to inhibit graft-versus-host disease (GVHD). GVHD
inhibition was reduced when Arg-1 deﬁcient MDSCs were
used.
iNOS can be induced in myeloid cells by diﬀerent tumor-
secreted factors such as VEGF, GM-CSF, and IL-6. MDSCs
expressing iNOS can inhibit mitogenic and peptide-speciﬁc
responses through NO production. MDSC-mediated T-cell
inhibition is associated with the impairment of the main
signaling pathways coupled to the IL-2 receptor as demon-
strated by the lack of JAK3, STAT5, extracellular signal-reg-
ulated kinase, and Akt phosphorylation in response to IL-2
[43].NOisabletoinduceareversibletypeofT-cellanergyby
reducing phosphorylation of tyrosine residues on JAK3 and
STAT5. NO also can reduce MHC-II expression, either by
downregulating IFN-γ-induced expression of class II trans-
activator or by inhibiting DNA binding of transcription fac-
t orNF -Yatthec lassIIpr omot erYbo x[44].MHC-IIexpres-
sion is critical for antigen-speciﬁc immunity. In a model of
MHC-mismatched rat kidney allograft, treatment with anti-
CD28 antibodies induced long-term survival and was as-
sociated with the presence, in tolerated allografts, of MDSCs
that operated through iNOS activity [15]. The action of NO
production was critical to the immunosuppression mediated
by MDSCs and in maintaining the tolerant state in vivo. In
this kidney transplantation model, the injection in tolerant
animals of amino guanidine, which inhibits iNOS, broke the
established tolerance and led to graft rejection. These results
suggest that MDSCs, accumulated in the blood of tolerant
kidney recipients, release high levels of NO after contact
with activated eﬀector T cells and speciﬁcally control their
proliferative response.
3.2. Heme Oxygenase-1 (HO-1). HO-1 catabolizes pro-oxi-
dant heme groups into carbon monoxide, biliverdin and fer-
ritin, three metabolites involved in immunoregulatory pro-
cesses[45,46].Recently,DeWildeetal.[29]reportedtheob-
servation of HO-1-dependent MDSCs-mediated alloreactive
T-cell suppression, which was cell-to-cell contact dependent
and requires IL-10 activity. They found that transfer of
MDSCs from LPS-treated mice in untreated recipients signi-
ﬁcantly prolonged skin allograft survival. To speciﬁcally ad-
dresstheroleofHO-1inthisMDSCs-mediateddelayofallo-
graftrejectionwastestedbyincubatingpuriﬁedMDSCswith
the HO-1-speciﬁc inhibitor SnPP pretreatment before an
adoptive transfer in female mice. SnPP treatment of MDSCs
abrogatedtheinhibitionofallograftrejection.Thisdemonst-
rates that HO-1 activity is a dominant eﬀector of in vivo im-
mune suppression mediated by MDSCs.
3.3. Radical Oxygen Species (ROS). The production of ROS
also contributes to the suppressive activity of MDSCs, as in-
creased ROS levels in MDSCs induce the upregulation of
severalsubunitsoftheNADPHoxidase[47].ROScaninduce
DNA damage in immune cells resident in the tumor micro-
environment, inhibit the diﬀerentiation of MDSCs into fun-
ctional dendritic cells, and recruit MDSCs to the tumor
site. Moreover, extracellular ROS catalyzes the nitration of
the TCR, which consequently inhibits the T-cell-peptide-
MHC interaction resulting in T-cell suppression [48]. The4 Clinical and Developmental Immunology
involvement of ROS in the suppressive activity of MDSCs is
notrestrictedtoneoplasticconditions.Indeed,inﬂammation
and microbial products are also known to induce the devel-
opment of an MDSC population that produces ROS follow-
ing its interaction with activated T cells.
3.4. Regulatory T Cells (Treg). Recently, MDSCs have been
shown to enhance the development of Treg, possibly through
interactions between CD80 expressed by MDSCs and CTLA-
4 expressed by Treg, production of IL-10, and/or preferential
inhibition of activated T cells through NO [35, 49]. In a
mouse model of lymphoma, MDSCs were shown to induce
Treg expansion through a mechanism that involved Arg-1
andthe capture,processing, andpresentation oftumor-asso-
ciated antigens by MDSCs but was independent of TGF-β
[50]. In a mice model of skin transplantation, recipents were
injected with recombinant G-CSF, or IL-2 complex(IL-2C),
Gr1+ CD11b+ MDSC or CD4+ Foxp3+ Treg were induced
in circulation of recipients [27]. They found that although
treatment with either IL-2C or G-CSF led to a signiﬁcant
delay of MHC-II disparate allogeneic donor skin rejection,
the combinatorial treatment was superior to either alone,
conﬁrming that MDSCs and Treg prolonged skin allograft
survival in mice. Karp and Mannon [51] summarized identi-
ﬁed an HLA-Dqα-class-II-derived peptide that was a potent
inducer of CD11b+CD115+Gr1+ MDSCs. Moreover, this
peptide prolonged the survival of fully mismatched mouse
cardiac allografts associated with the induction of Foxp3+
Treg. Depletion or inhibition of function of MDSCs reversed
the prolonged survival and decreased Treg in the recipient.
3.5. CD8+ T Cells. MDSCs can take up soluble antigens,
including tumor-associated antigens, and process and pre-
sent them to T cells. Blocked MDSCs-T cells interactions
with a MHC-I speciﬁc antibody abrogate MDSC-mediated
inhibition of T-cell responses in vitro. The MHC-I restricted
nature of MDSC-mediated CD8+ T cell suppression has also
beendemonstratedinvivointumormodels[52,53].MDSCs
can abrogate the expression of L-selectin on CD8+ T-cell,
suppressingthehomingofthesecellstothetumorsite,where
they would be activated. MDSCs cleave L-selectin from T
cells because they constitutively express ADAM17 at their
cell surface and, as a result, T cells cannot traﬃct ot u -
mor draining lymph nodes, where they normally would have
access to tumor antigens and consequently can not be acti-
vated [54]. One study showed a potential mechanism for IL-
10- and IFN-γ-dependent MDSCs regulation of CD8+ T cell
functionmediatedthroughprogrammedcelldeath-1(PD-1)
andPD-1ligandinteraction[55].TheytestiﬁedthePD-1sig-
naling pathway inducing the apoptosis of CD8+ T cells and
phagocytosed CD8+ T cells, contributing to CD8+ T cell
exhaustion. However, whether PD-1 signaling pathway plays
a role in MDSCs-mediated T cell suppression remains cont-
roversial, and further investigations are needed.
3.6. T-Helper 2 (Th2) Cells. A recent study found that
MDSCscanimpairtumorimmunitynotonlybysuppressing
T-cell activation but also by interacting with macrophages to
increase IL-10 and decrease IL-12 production, thereby pro-
moting a tumor-promoting type 2 response [56]. Many liter-
atures have reported that MDSCs inhibit antigen-speciﬁc
and nonspeciﬁc T-cell functions via several diﬀerent mech-
anisms, including Arg-1, NO, ROS, IL-10, and TGF-β [35].
Furthermore, using a depleting antibody, Delano et al. [57]
demonstrated that expansion of MDSCs in vivo contributed
to the induced Th2 polarization of antibody responses after
sepsis. Challenging mice with T-cell-dependent antigens,
suchasNP-KLH,oﬀerstheopportunitytoexploreinvivothe
shift in antibody class switching to IgG2a or IgG1 production,
which is dependent on cytokines, including IFN-γ and IL-
4, and reﬂects this predilection toward a Th2 versus a Th1
CD4+ T-cell response. Turnquist et al. [31] found that IL-33
administration greatly increased splenic MDSCs in normal
and transplanted mice. It has been suggested that IL-33
prolongs cardiac allograft survival by promoting Th2 res-
ponses. Administration of IL-33 concurrent with cardiac
allotransplantation increased systemic levels of IL-5 and IL-
13, increased IL-5+CD4+ cells, and decreased CD8+INF-γ+
T cells. Notably, IL-13 is implicated in tolerance, particularly
by targeting myeloid cells and activating the suppressive
function of MDSCs.
4. Summary
MDSCs aid tumor development by exerting a profound
inhibitoryactivityonTcells.ThemechanismofMDSCspos-
sessing a direct role in the inhibition of T-cell function is well
established in tumors. Their potential role in organ trans-
plantation requires far more investigation. Recently, Qian’s
group have found that cotransplantation with in vitro gener-
ated MDSCs can eﬀectively protect islet allografts from
host immune attack [30]. Our study also demonstrated that
MDSCs can be propagated in vitro from bone-marrow-
derived myeloid precursor cells under the inﬂuence of hep-
atic stellate cells. Adoptive transfer of these in vitro generated
cells can prolong cardiac allograft survival. However, the
mechanism of MDSCs causing immunosuppression in this
modelhasnotyetbeenexplored.Adetailedunderstandingof
MDSCs regulation of T-cell immune function in transplan-
tation will undoubtedly lead to the design of more eﬀective
strategies to achieve transplant tolerance in the clinic.
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